AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Anteris adds two independent directors to its board.
- Governance reshuffle supports pivotal clinical phase.
- Strong alignment with shareholder interests through equity-linked compensation.
Anteris Technologies (ASX:AVR), a developer of transcatheter heart valve technologies, has announced significant updates to its boardroom, reflecting its ongoing focus on governance excellence and clinical progress. The company has appointed Gregory Moss and David Roberts as independent directors, both bringing substantial industry and leadership experience to the fold.
These appointments were made effective on June 7, 2025 (USA) / June 8, 2025 (Australia), and align with Anteris’ commitment to strengthening its oversight capabilities as it enters a capital-intensive phase of its global pivotal trial for the DurAVR® transcatheter heart valve system. This move reinforces the company's strategic positioning within the healthcare segment of the ASX200.
Gregory Moss, now a Class I Director until 2025, contributes a strong background in legal and business development. Moss currently serves as Chief Business and Legal Officer at Evommune Inc. and played a critical role in Kadmon’s acquisition by Sanofi, valued at US$1.9 billion. At Anteris, he joins the Nominating and Corporate Governance Committee.
David Roberts, serving as a Class III Director through 2027, is the President of LeMaitre Vascular Inc. since 2007 and brings comprehensive financial and operational leadership. His past roles at BUCA Inc. and HarbourVest Partners position him well to contribute to Anteris' Audit and Risk Committee and the Compensation Committee.
This reshaping of the board follows the resignation of Dr Wenyi Gu, whose departure was officially acknowledged on June 5, 2025 (USA) / June 6, 2025 (Australia). Anteris confirmed that the resignation was amicable and not associated with any governance-related disagreements. The company expressed appreciation for Dr Gu’s contributions during his tenure.
As part of their onboarding, both Moss and Roberts are set to receive equity grants of US$250,000, structured to vest over three years, alongside prorated annual awards and cash retainers. These compensation elements are in accordance with Anteris’ Non-Employee Director Compensation Policy and are subject to shareholder approval through the ASX. Indemnification agreements have also been established, ensuring legal protections under Delaware law.
This strategic realignment at Anteris not only prepares the company for an intensive clinical phase but also strengthens its corporate governance as it continues to appeal to investors looking at promising ASX dividend stocks in the biotechnology space. With its positioning within the S&P/ASX200 framework, Anteris remains a noteworthy player to observe in the evolving healthcare landscape.
